GOLPH3 and neoplasm: A total of 62% of patients (44 out of 71) with low expression levels of GOLPH3 showed tumor down-staging after nCRT; in contrast, only 43% (33 out of 77) with GOLPH3 overexpression in tumor tissue showed down-staging after nCRT (p = 0.020) [48].